The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Questcor to Participate in Upcoming Conferences

Thursday, July 29, 2010

Questcor to Participate in Upcoming Conferences06:30 EDT Thursday, July 29, 2010UNION CITY, Calif., July 29 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will participate in the following upcoming investor conferences: The BMO Capital Markets 10th Annual Focus on Healthcare ConferenceThursday, August 5, 2010New York, NY4:00 p.m. ETWebcast available at: Stewart 2010 Health Care EventWednesday, August 11, 2010New York, NYAttendance at these conferences is by invitation only. Don M. Bailey, President and Chief Executive Officer, and Dr. David Young, Chief Scientific Officer, will discuss the Company's business strategy and historical financial performance.About QuestcorQuestcor Pharmaceuticals is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. For more information, please visit Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776,; or Investors, Doug Sherk, +1-415-896-6818, or Media, Christopher Gale, +1-646-201-5431, both of EVC Group, Inc., for Questcor Pharmaceuticals, Inc.